Synthesis of PET-Tracers

Proof-of-concept for automated synthesis of PET-Tracers

This tab outlines the result of a cooperative development of ABX GmbH and GESIM mbH, initiated by a BMBF supported joint research project (FKZ: 13N10271).

To conduct a PET scan, a short-lived radioactive tracer isotope is injected into the living subject (usually into blood circulation). The tracer is chemically incorporated into a biologically active molecule in order to fit a particular medical indication.

The tracer isotope cannot be produced in advance but must be synthesized shortly before the PET scan. On the other hand, the manipulation of radioactive components requires stringent work protection measures for the clinical staff.

MSRP3.1 with with reactor (left) and ABX kit plates (right)

BSys 3.1 with with reactor (left) and ABX kit plates (right)

BSyS 3.1 allows the unattended synthesis of multiple radioactive tracers for different medical indications. It brings up productivity of the PET facility to a new level:

  • Up to eight validated synthesis per day
  • Novel synthesis procedure established for [18F]FDG, [18]FLT, [18]FMISO, [18]FNaF, [18]FES, [18F]FET, [18]FSB-peptides and [68Ga]GA-peptides
  • 8 Kit plates featuring reactor, reagent and SPE purification and separate canulla reservoirs

This version of BSyS 3.1 still needs to be evaluated and certified for use with PET scanners in a clinical environment. Research groups from Roskilde and Copenhagen, Denmark, have used the BSyS 3.1 to develop Ti-containing cytotoxic compounds without cisplatin cross-resistance. However, at present no protocol exists that is working out of the box.